
Please try another search
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Name | Age | Since | Title |
---|---|---|---|
Steven R. Gannon | 64 | 2015 | Independent Director |
Elizabeth A. Garofalo | 66 | 2021 | Independent Director |
Justin D. Gover | 54 | 2023 | Independent Director |
Gary Patou | 66 | 2004 | Independent Director |
C. Patrick Machado | 61 | 2020 | Independent Director |
Gillian M. Cannon | 60 | 2023 | Independent Director |
Dawn A. Svoronos | 72 | 2016 | Independent Chairman & Lead Independent Director |
Ian C. Mortimer | 49 | 2015 | Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review